Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 33 results found. Search for [ Gilead Sciences Inc ]

Results 1 to 21 of 33
BusinessToday.In
July 1, 2020
Remdesivir supply: US Department of Health and Human Services said it has secured 500,000 treatment courses of remdesivir for American hospitals through September


Reuters
June 25, 2020
Cipla and Hetero are among a bevy of drugmakers which have licensing agreements with US-based Gilead Sciences Inc, the original manufacturer of remdesivir, to make and sell the drug in 127 low- and middle-income countries


Reuters
June 23, 2020
Indian drugmakers Hetero Labs and Cipla Ltd on Sunday gained approval to begin selling their generic versions of remdesivir in the country


E Kumar Sharma
New Delhi, June 21, 2020
Cipla plans to launch the drug in a couple of days, while Hetero's drug is expected to hit the market in a week


BusinessToday.In
June 21, 2020
COVID-19 vaccine latest news update: The phase-2 trial will evaluate the shot's dose and continue to determine whether the potential vaccine can safely trigger immune responses in healthy people


Chitranjan Kumar
New Delhi, June 19, 2020
On progress on treatment options for COVID-19, Cadila said it is working on a DNA vaccine to fight coronavirus, which is currently in the animal testing stage


BusinessToday.In
June 15, 2020
Stock Market LIVE Updates: IndusInd Bank, followed by Tata Steel, Bajaj Finance, ICICI Bank, Axis Bank, NTPC, SBI, HDFC Bank and SBI were among the top laggards in the Sensex pack. On the other hand, Sun Pharma, Infosys, Nestle India and Asian Paints were among the top gainers


BusinessToday.In
June 15, 2020
Stocks to watch today on June 15: Hindalco Industries, Dr Reddys, Lupin, PNB Housing, BHEL, UTI AMC, Eicher Motors, RIL, MCX among others are the top stocks to watch out for in Monday's trading session


Associated Press
June 13, 2020
Four companies -- Hetero, Jubilant Life Sciences, Cipla and Mylan NV -- with which the original drug maker, Gilead Sciences Inc, have entered into non-exclusive licensing agreements are still awaiting nod from the DCGI for manufacturing and selling of remdesivir in India


BusinessToday.In
New Delhi, June 13, 2020
COVID-19 vaccine and drug latest news update: Gilead Sciences Inc had previously signed pacts with five other companies for manufacturing and sale of remdesivir; here are latest updates from across world on coronavirus vaccine developments


BusinessToday.In
New Delhi, June 11, 2020
Coronavirus vaccine update: Johnson and Johnson has said that it has pushed up clinical trials by two months; Japanese biotech company AnGes Inc expects its coronavirus vaccine to be ready by the first half of 2021 if production and supply goes smoothly


BusinessToday.In
June 10, 2020
In China, an activated experimental corona vaccine developed by scientists  has shown effective protection against COVD-19 infection in animal trials


Reuters
June 2, 2020
Remdesivir is the first drug to show improvement in COVID-19 patients in formal clinical trials


PTI
June 2, 2020
The drug has been allowed for restricted emergency use for treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children hospitalised with severe symptoms, subject to several safeguards, the source said


PTI
May 30, 2020
Gilead Sciences Inc have entered into non-exclusive licensing agreements with pharma firms including three domestic majors Cipla, Jubilant Life Sciences and Hetero for manufacture and distribution of remdesivir


BusinessToday.In
May 24, 2020
Coronavirus vaccine update: Experts have welcomed the findings, saying the results showed patients on remdesivir cut their recovery time by 27 per cent


Reuters
May 22, 2020
The FDA approved emergency use of remdesivir on May 1 based on preliminary results from a National Institute of Allergy and Infectious Diseases (NIAID) trial showing that the drug cut hospital stays by 31%, or about four days, compared with a placebo


Reuters
May 16, 2020
Interest in Gilead's drug has been high given some promising early data and the lack of approved treatments or preventive vaccines for COVID-19, the disease caused by the novel coronavirus


Reuters
May 15, 2020
Gilead on Tuesday said it had signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of remdesivir in more than 120 mostly low-income countries in Southeast Asia, Africa and other parts of the world


BusinessToday.In
May 9, 2020
Coronavirus vaccine: World leaders and organisations, except the United States, have already pledged $8 billion to research, manufacture and distribute a possible vaccine and treatments for COVID-19 apart from the individual efforts taken by the countries and its pharmaceutical firms


PAGES 1 OF 2  12